Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK reports that China’s National Medical Products Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with chronic obstructive pulmonary disease (COPD) that remains inadequately controlled and is characterised by raised blood eosinophils. The decision is based on positive phase III MATINEE and METREX trials, where mepolizumab plus standard care produced a statistically significant reduction in the annual rate of moderate or severe COPD exacerbations versus placebo, including events leading to emergency department visits and hospitalisation.
Nucala is described as the first and only monthly biologic in China studied in a broad COPD population with blood eosinophil counts starting at 150 cells/µL. GSK notes that around 100 million people in China are living with COPD and that among patients who continue to exacerbate despite inhaled triple therapy, about 67% have blood eosinophil counts above 150 cells/µL, suggesting a substantial segment of patients who may be eligible for this new add-on treatment option.
GSK plc has entered into an agreement with the U.S. Administration to lower the cost of its prescription medicines for American patients, including its broad respiratory portfolio used by more than 40 million people in the U.S. with asthma and COPD. The agreement delivers on all four actions requested by President Trump in his July 31 letter, including lowering prices for certain medicines in Medicaid and launching new products with a more balanced pricing approach across developed nations.
GSK will also offer most of its inhaled respiratory portfolio and other products through a direct purchasing platform that can provide savings of up to 66% for patients. As part of the President's Strategic Active Pharmaceutical Ingredients Reserve, GSK will secure a U.S. reserve of albuterol, a key ingredient in many inhalers. The agreements cover both GSK and ViiV Healthcare, clarify the future U.S. pricing framework, and exclude them from s232 tariffs for three years. GSK reiterates its plan to invest more than $30bn in U.S. R&D and manufacturing over five years, including $2bn of new commitments that are expected to create hundreds of highly skilled U.S. jobs.
GSK plc disclosed several share purchases by board members and a person closely associated with the Non-Executive Chair. On 19 December 2025, Independent Non-Executive Director Wendy Becker bought 441 ordinary shares at £18.0909 each on the London Stock Exchange. On the same date, Independent Non-Executive Director Elizabeth (Liz) McKee Anderson bought 201 American Depositary Shares (ADSs) at $48.5550, Senior Independent Non-Executive Director Charles Bancroft bought 1,577 ADSs at $48.5550, and Independent Non-Executive Directors Dr Anne Beal, Dr Hal Dietz and Dr Jeannie Lee purchased 201, 201 and 202 ADSs respectively at $48.5550 on the New York Stock Exchange. Dr Vishal Sikka acquired 730 ADSs at $48.5550 on the same date. On 22 December 2025, Lady Susan Symonds, a person closely associated with the Non-Executive Chair, purchased 1,650 ordinary shares at £18.1046 on the London Stock Exchange.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 232,912 of its ordinary shares on 19 December 2025 as part of its existing share buyback programme. The shares were bought at prices between 1,798.50p and 1,818.00p, with a volume-weighted average price of 1,807.58p, and will be held as treasury shares.
Since 30 September 2025, GSK has repurchased 14,554,645 ordinary shares under this programme. After the latest transactions, the company holds 240,019,489 shares in treasury and has 4,075,425,537 ordinary shares in issue, which is also the total number of voting rights. GSK states that, in line with regulatory rules, 5.89% of its voting rights are now attributable to shares held in treasury.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 235,000 ordinary shares of 31¼ pence each on 18 December 2025. The shares were bought at prices between 1,797.50p and 1,820.00p per share, with a volume-weighted average price of 1,810.34p, and will be held as treasury shares as part of its existing buyback programme under a non-discretionary agreement.
Since 30 September 2025, GSK has repurchased 14,321,733 ordinary shares. After this latest transaction, it holds 239,786,577 shares in treasury and has 4,075,654,506 ordinary shares in issue, which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is 5.88%.
GSK plc repurchased 235,000 ordinary shares of 31¼ pence each on 17 December 2025 as part of its existing share buyback programme, acting through BNP Paribas SA. The shares were bought between 1,824.00p and 1,850.00p per share, with a volume-weighted average price of 1,841.56p, and will be held as treasury shares.
After this transaction, GSK will hold 239,551,577 ordinary shares in treasury and have 4,075,889,506 ordinary shares in issue (excluding treasury shares), giving the same number of voting rights. The percentage of voting rights attributable to the treasury shares is 5.88 per cent.
GSK plc reported that Europe’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending approval of depemokimab for two uses: severe asthma with type 2 inflammation and severe chronic rhinosinusitis with nasal polyps (CRSwNP). If approved, depemokimab would be the first ultra-long-acting biologic for respiratory disease in the EU, given as just two doses a year. The opinion is based on four phase III trials showing a 54% reduction in clinically significant asthma exacerbations over 52 weeks and a 72% reduction in exacerbations requiring hospital or emergency department care, versus placebo plus standard treatment. In CRSwNP, depemokimab improved nasal polyp size and nasal obstruction scores. The European Commission decision is expected in Q1 2026, and depemokimab is not yet approved anywhere.
GSK plc reported that the European Medicines Agency’s CHMP has issued a positive opinion recommending approval of Nucala (mepolizumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils who are already on inhaled triple therapy. The opinion is based on the phase III MATINEE trial, where Nucala reduced the annual rate of moderate or severe COPD exacerbations versus placebo when both were added to triple therapy, with a rate ratio of 0.79 and similar overall adverse event rates between groups.
A pre-defined secondary analysis showed Nucala also lowered exacerbations that led to emergency department visits and/or hospitalisations compared with placebo. Nucala is already approved in Europe for four eosinophilic and type 2 inflammatory conditions and received US approval for COPD in May 2025. The European Commission decision on this new COPD indication is expected in Q1 2026, which could expand treatment options for patients whose disease remains uncontrolled.
GSK plc reports that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion to expand the indication of its RSV vaccine Arexvy to all adults aged 18 years and older. A final decision from the European Commission is expected in February 2026, which, if approved, would allow use across the full adult population.
Arexvy is already approved in Europe for preventing lower respiratory tract disease caused by RSV in adults 60 and older, and in adults 50–59 at increased risk. RSV is described as a common respiratory virus that can cause severe disease, with an estimated 64 million people affected globally every year and around 158,000 adults aged 18 and over hospitalised annually in the EU. GSK is also pursuing expanded indications in other regions, including the US and Japan.
GSK plc reports that it repurchased 217,000 ordinary shares on 11 December 2025 through BNP Paribas SA as part of its existing share buyback programme. The shares, bought at prices between 1,793.00p and 1,820.00p with a volume‑weighted average price of 1,807.53p, will be held in treasury. Since 30 September 2025, the company has bought 13,161,733 ordinary shares under this programme. After this latest transaction, GSK holds 238,626,577 shares in treasury and has 4,076,812,560 ordinary shares in issue, which is also the total number of voting rights. The company states that treasury shares now represent 5.85% of its voting rights.